Post Panels, Telaprevir And Boceprevir Now Face FDA's Risk Management Review

Coming out of FDA’s Antiviral Drugs Advisory Committee reviews with ringing endorsement for both Vertex Pharmaceuticals’ telaprevir and Merck’s boceprevir, the attention now shifts to risk management for the anemia associated with both protease inhibitors for hepatitis C and for rash associated with telaprevir.